Date of publication: August 24, 2021 Approved by the Secretary of Health: September 01, 2021 Evidence Summary: Tenofovir/Lamivudine/Dolutegravir for treatment-naive and treatment-experienced adolescents and adults living with HIV Advisory on non-inclusion in PNF: https://bit.ly/PR_TLD HTAC Recommendation Review:
Effectiveness and Safety of Pazopanib in the Management of Metastatic Soft Tissue Sarcoma Post-Chemotherapy
Evidence Summary: effectiveness and safety of pazopanib in the management of metastatic soft tissue sarcoma post-chemotherapy
Favipiravir
I. Assessment A. Policy and Research Question Policy Question: Should the Philippine government introduce favipiravir as an add-on to the DOH-PSMID-recommended treatment regimens for patients with COVID-19 versus the DOH-PSMID recommended guidelines as of March 31? Research Questions: B. Protocol: Not available. C. Reviewers: Health Technology Assessment Unit, DOH D. Start of Review: March 26, 2020 E. End continue reading : Favipiravir
Cycloferon
I. Assessment A. Policy and Research Question Policy Question: Should the Philippine government accept the donation and introduce MA as an add-on to the DOH-PSMID-recommended treatment regimens for patients with COVID-19 versus the DOH-PSMID recommended guidelines as of March 31? Research Questions: B. Protocol: Not available. C. Reviewers: Health Technology Assessment Unit, DOH D. Start of Review: March continue reading : Cycloferon